Elixophyllin(Theophylline Anhydrous)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$6,650
Medicare cost, 2023
$6,650
Medicare cost, 2023
Medicare drug plans spent on Elixophyllin (theophylline anhydrous) in 2024, for prescriptions and refills. Spending fell 68% from 2022 to 2023.
Medicare cost, 2023
$6,650
-67.8% from 2022
Prescriptions
21
$316.68 per claim
Patients
-
5 prescribers
Total spending
-
All plans
Questions and answers
How much does Medicare spend on Elixophyllin?
Medicare prescription drug plans paid $6,650 for Elixophyllin in 2023, for 21 prescriptions and refills to - patients (down 67.8% from 2022). The average cost per claim was $316.68.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 12 | 25 | - | $21K |
| 2023 | 5 | 21 | - | $6,650 |
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 12,470 side-effect reports named theophylline anhydrous, the active ingredient of Elixophyllin (reports from 1995 on). 10,214 of them (81.9%) were serious, 1,794 named a death and 5,406 named a hospital stay. The reactions named most often were dyspnoea, asthma and pneumonia. 2,993 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
12,470
636 in 2025 (-2.0% from 2024)
Serious
81.9%
10,214 reports
Deaths named
1,794
14.4% of reports
Hospital stays
5,406
43.4% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
Since 2002. 2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Elixophyllin?
12,470 reports from 1995 through September 2026 named theophylline anhydrous, the active ingredient of Elixophyllin. 10,214 of them (81.9%) were serious, 1,794 named a death and 5,406 named a hospital stay.
What are the most reported side effects of Elixophyllin?
2,502 reports named dyspnoea, the reaction named most often, followed by asthma (2,155) and pneumonia (1,517). In the last 5 years the reaction named most often was asthma (1,107 reports). A report can name several reactions.
How many side-effect reports named Elixophyllin in 2025?
636 reports were received in 2025 (-2.0% from 2024). 2026 so far: 459 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Elixophyllin caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Elixophyllin caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with theophylline anhydrous: Theophylline Er, Theo-24
- Drug approvals (4 approvals on file for theophylline anhydrous) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (theophylline anhydrous) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.